

INDEX

A

abbreviations, 118, 173, 197
absolute measures
 absolute risk reduction/increase, 93–94
 defined, 92
 number needed to harm (NNH), 95
 number needed to treat (NNT), 94
absolute risk increase (ARI), 94, 95
absolute risk reduction (ARR), 94
absolute risk reduction/increase, 93–94
abstract
 of manuscript, 190, 202–203
 preparation, 171–174
 authorship, 172
 background/purpose, 172
 conclusions, 173
 formatting, 172
 methods, 172
 results, 173
 style, 173
 tips for writing, 173–174
 title, 172, 173
 sample of, 185
 of study protocol, 19
 submitting to conference/professional meeting, 174
Academy of Managed Care Pharmacy (AMCP), 164
acknowledgments
 in manuscript, 193, 204
 in platform presentations, 179
acronyms, 173
adaptive randomization, 28
administrative data, 62
Adverse Events Reporting System Public Dashboard (FDA), 40
Agency for Healthcare Research and Quality, 161
alpha (α), 87
alternative hypothesis, 12–13
ambispective studies, 25, 31, 35
American Society of Health Economists (ASHEcon), 164
American Society of Health-System Pharmacists (ASHP), 164
analysis of covariance (ANCOVA/ANACOVA), 85
analysis of variance (ANOVA), 83, 84
analytical plan, in study protocol, 19
analytic study design, 22, 24, 27–29
 quasi-experimental designs, 22, 23, 28–29
 randomized/interventional studies, 22, 23, 25, 27–28
anonymity in surveys, 137
appendixes, in study protocol, 19
associative hypothesis, 12–13
ATLAS.ti, 124
attributable risk, 93–94
attrition bias, 34
audience, engaging, 176–177
audit trail, 125
authorship
 in abstract preparation, 172
 criteria, 195–197
 roles, 196–197
autobiography, 106
average wholesale price (AWP), 161

B

background/purpose
 in abstract, 172
 in manuscript, 190
 in study protocol, 19
bar graphs, 180
base case scenario, 153, 157
Belmont Report, 41
beta (β), 87
bias
 confounding, 32, 34–35
 history, 29
 maturation, 29
 nonresponse, 134, 140, 141
 reporting, 33
 response, 141
 in survey research, 141–142
 types of, 33–34
 in validity, 32–35
 wish, 33
BibMe, 9
biographical study, 106
biostatistician, when to consult, 88
biostatistics, 75–90
 defined, 76
 descriptive statistics, 78–81
 inferential statistics, 81–86
 sample size, estimation of, 87–88
 statistical software, 86
 study statistics, recommendations for, 88
 variable types, 76–77
bivariate comparisons, 140
block randomization, 27
bounding the case, 108
Box, 112
budget impact analysis (BIA), 148, 149, 151–152, 160

C

case analysis, 108
case-control studies, 22, 24, 30–31
case report or case series, 22, 25–26
case studies, 105, 107–108
categorical variables, 76
category, 124
causal hypothesis, 12–13
causality, 27, 30
causal research questions, 3
Centers for Medicare & Medicaid Services (CMS), 161
central tendency, measures of, 77, 78–79
charges, 162
checkboxes, 138
chi-square (χ^2) test, 82, 83
Cite This For Me, 9
Clinical Laboratory Fee Schedule, 161
clinical significance, statistical *versus*, 99
Cloud storage, 112
cluster randomized trials, 28

co-authors, 195–197
 authorship criteria, 195–197
 feedback, 197

Cochran–Mantel–Haenszel test, 82, 83

codebook, 122–123

code data, 123–124

Code of Federal Regulations, 40

coding frame, 65, 67, 122–123

coercion, 50

cognitive interviewing, 139

cohort, defined, 31

cohort studies, 22, 24, 25, 31–32
 prospective, 25, 31
 retrospective, 25, 31, 32

collaborating with research team, 13–14
 items for discussion, 14
 successful collaborations, 14

Collaborative Institutional Training Initiative Program, 42

Common Procedural Terminology (CPT) codes, 161

Common Rule, 40, 41, 44
 Revised, 41, 43, 44

compensation, 162

complex vocabulary questions, 136

conceptual framework, 114

conclusions
 in abstract, 173
 in manuscript, 193, 203

confidence intervals, 98–99

confidentiality, in surveys, 137

confirmability, of qualitative research, 125

conflicts of interest, in manuscript, 193, 204

confounder, 85

confounding bias, 32, 34

consent form, 48. *See also* informed consent

Consolidated Criteria for Reporting Qualitative Research (COREQ), 126, 191

Consolidated Health Economic Evaluation Reporting Standards (CHEERS), 165

contingency table, 92

continuous data, statistical tests for, 83–84

continuous variables, 76–77

contractions, 173

control group, 27

controls, 29–30

convenience sample, 114, 132–133

copyright permissions, in manuscript, 193

correlation, 83

cost-benefit analysis (CBA), 148, 150

cost data, 161–162
 costs *versus* charges, 162
 direct medical costs, 161
 direct non-medical costs, 161–162
 discounting, 156–157
 in economic model, 156–157
 estimating, 161
 indirect costs, 162
 inpatient costs, 161
 institution-specific costs, 161–162
 outpatient costs, 161

cost-effectiveness acceptability curve, 159

cost-effectiveness analysis (CEA), 148, 150–151, 164, 165

cost-effectiveness planes, 159, 160, 164

cost-effectiveness quadrant diagram, 160

cost-minimization analysis (CMA), 148, 150

cost-of-illness (COI) analysis, 149–150

cost-utility analysis, 150–151

Council for International Organization of Medical Sciences Guidelines, 41

coverage bias, 141

cover letter, for manuscript, 188, 202

Cox proportional hazards regression, 86, 97

credibility, of qualitative research, 125

criterion sampling, 115

critical case sampling, 114

critical sampling, 114

Cronbach's alpha values, 140

cross-sectional studies, 22, 23, 26–27

cross-sectional surveys, 26

cross-tabulation, 82

D

data. *See also* study data
 distribution of, normal *versus* non-normal, 80–81
 outcomes and quality-of-life, 162–163
 in pharmacoeconomic analyses
 cost, 161–162
 outcomes and quality-of-life data, 162–163
 presentation of, 164–165, 169
 privacy, 111
 problems and limitations of, 70–72
 data quality, 71
 duplicate data, 71
 missing data, 70
 outliers, 71
 recording, 112
 scaling, 140
 security, 139
 sources, 62
 storage, 112–113, 139
 summarized, in table using descriptive statistics, 78
 variability, measures of, 79–80

data collection
 defined, 61
 format, 109–110
 inclusion and exclusion criteria, 36
 location of, 112
 study population, 36
 timeframe, 35

data collection methods, 108–121
 focus groups
 defined, 109–110
 ground rules for, 111
 individual interviews *versus*, 110
 length of, 116
 location of, 116
 moderating, 117
 probing during, 118–119
 recruitment of participants and sampling strategies, 114–115
 sample size in, 115–116

interviews
 asking questions, 118
 conducting, 116–117
 ground rules for, 111
 individual *versus* focus groups, 110
 interview guide, creating, 119–121
 length of, 116
 location of, 116
 overview of, 113
 planning, 114–121

probing during, 118–119
 recruitment of participants and sampling strategies, 114–115
 sample size in, 115–116
 types of, advantages and disadvantages of, 120–121
 IRB considerations in, 111–113
 informed consent, 111
 location of data collection, 112
 number of participants, 111–112
 recording data, 112
 storing data, 112–113
 use of incentives, 112
 overview of, 109
 seven key steps, 108–111
 access to participants, 108–109
 data collection format, 109–110
 data privacy, 111
 field issues, 110–111
 identify sample size, 109
 population of focus, 108
 process for documenting information, 110
 data collection platforms, 68–70
 electronic data capture tools, 70
 Microsoft Excel or similar spreadsheet tool, 68, 69
 statistical software, 68, 69
 data collection tool, 64–69
 coding frame, 65, 67
 data collection platforms, 68–70
 data dictionary, 65–68
 list of variables, 64–65
 real-world example, 67–68
 tips for creating and using, 69
 data dictionary, 65–68
 data extraction errors, 71
 data source triangulation, 125
 data transcription, 121–122
 debriefing, 125
 decision tree, 148, 153, 154
 Declaration of Helsinki, 41
 Dedoose, 124
 deductive approach, 123
 de-identification of study data, 48
 delivering presentation, 181–183
 key tips for, 181–182
 questions, responding to, 182
 Department of Defense, 40
 dependability, of qualitative research, 125
 dependent variable
 confounding bias and, 32, 34
 defined, 32
 descriptive research questions, 3
 descriptive statistics, 78–81
 data summarized in table using, example of, 78
 defined, 78
 distribution of data, normal *versus* non-normal, 80–81
 measures of central tendency, 78–79
 measures of data variability, 79–80
 in sample responses, 139
 descriptive study designs, 22, 25–27. *See also* qualitative research
 case report or case series, 22, 25–26
 cross-sectional studies, 22, 23, 26–27
 deviant case selection, 115
 dichotomous questions, 118
 dichotomous variables, 76, 77
 difference-in-difference (DID) analysis, 86
 directional hypothesis, 12–13

direct medical costs, 161
 direct non-medical costs, 161–162
 direct quotes, 125
 discounting, 148, 156–157
 discrete variables, 76, 77
 discussion, in manuscript, 192–193, 203
 dispersion, measures of, 77
 documenting information, process for, 110
 double-barreled questions, 136
 double-negative questions, 136
 Dropbox, 112
 drug interactions involving direct oral anticoagulants (DOACs), 25
 duplicate data, 71

E

economic model
 building, step-by-step guide, 152–160
 checklist for, 165–166
 costs and discounting, 156–157
 model perspective, 155
 model structure, determine, 153–155
 summary of, 160
 target population, 155
 time horizon, 155–156
 key features of, 153
 presentation, elements of, 164–165, 169
 software for running, 163
 structure of, 153–155
 base case scenario, 153, 157
 decision tree, 153, 154
 Markov model, 153, 155
 uncertainty analysis, 157–160
 electronic data capture tools, 70, 71
 electronic data storage, 112
 electronic/web-based surveys, 134
 encoding key, 112
 encore presentation, 174
 EndNote, 10, 194
 endpoint, 13
 Enhancing Transparency in Reporting the Synthesis of Qualitative Research (ENTREQ), 126, 191
 ethical codes and laws, 41
 ethnography, 105, 107
 Excel spreadsheets, 9, 68, 69
 exclusion criteria, 36
 exempt research categories, 45–46
 exempt review, 44–46
 expedited research categories, 55–56
 expedited review, 44, 46
 expert reviewers, 197
 exploratory perspective, 123
 external audits, 125
 external validity, 32–35
 of quantitative research, 125
 extreme or deviant case selection, 115

F

face-to-face interviews, 113, 116, 133, 142
 false negative, 87
 false positive, 87
 false sense of security, 124
 Family Educational Rights and Privacy Act, 40

Federal Policy for the Protection of Human Subjects, 40
 feedback, from co-authors, 197
 field issues, 110–111
 FINER criteria, 6–7
 ethical, 7
 feasibility, 6–7
 interesting, 7
 novel, 7
 relevant, 7
 first right of refusal, 174
 Fisher's exact test, 82, 83
 fixed-response questions, 135–136
 flowcharts, 180
 focus groups
 in conjunction with professional meeting, 113
 defined, 109–110
 ground rules for, 111
 individual interviews *versus*, 110
 interviews compared to, 110–111
 length of focus group, 116
 location of, 116
 moderating, 117
 planning, 114–121
 probing during, 118–119
 recruitment of participants and sampling strategies, 114–115
 sample size in, 115–116
 Food and Drug Administration (FDA), 40
 formatting
 abstract, 172
 IMRaD format, 190
 journal, 188
 poster presentations, 175–176
 Friedman ANOVA, 85
 full board review, 44, 46
 funnel method, 120, 121

G

Gantt chart, 15–16
 generalizable knowledge, 40
 general reviewers, 197
 Google Drive, 112
 Google forms, 139
 Google Voice, 112
 GoToMeeting, 112
 GraphPad, 86
 grounded theory, 105, 106–107

H

halo effect questions, 136
 hazard ratios (HRs), 97–98
 Healthcare Common Procedure Coding System (HCPCS), 161
 Healthcare Cost and Utilization Project (HCUP), 161
 Health Insurance Portability and Accountability Act (HIPAA), 40, 41, 43, 48, 112, 134
 health-system perspective, 155
 heterogeneous group, 113
 high facilitator involvement, 117
 highly structured interview, 120
 history bias, 29
 homogenous group, 113

human subjects research, 40–41
 hypothesis, 12–13
 statements, 12–13
 testing, inferential statistics and, 81

IBM Micromedex RED BOOK, 161
 identifiable private information, 40
 illustrations, 180
 impact factor, 188
 IMRaD format, 190
 incentives, 112
 in surveys, 138
 incidence, 26, 30
 inclusion criteria, 36
 incremental budget impact, 152
 incremental cost-effectiveness ratio (ICER), 149, 159, 160, 164, 169
 independent variables
 confounding bias and, 32, 34
 defined, 32
 in-depth interviews (IDIs), 106, 110, 113, 116. *See also* interviews
 indexing tool, 197
 indirect costs, 162
 inductive approach, 114, 123
 inferential statistics, 81–86
 difference-in-difference analysis, 86
 hypothesis testing, 81
 multivariable regression analysis, 85–86
 statistical tests, 82–85
 for continuous data, 83–84
 for nominal data, 82–83
 for ordinal or skewed data, 84–85
 information bias, 33
 informed consent
 IRB considerations, 111, 137
 study participants, 48–49
 creating, 48–49
 elements of, 48
 verbal, 49, 56
 waiving requirement for, 48, 111
 written, 49, 57–59, 111
 inpatient costs, 161
 Institutional Review Board (IRB), 39–55
 approval process, 41–43
 questions about, 42–43
 considerations for surveys, 137–138
 anonymity and confidentiality, 137
 incentives, 138
 informed consent, 137
 introductory statement, 137, 145
 protocol modifications, 138
 data collection methods, 111–113
 informed consent, 111
 location of data collection, 112
 number of participants, 111–112
 recording data, 112
 storing data, 112–113
 use of incentives, 112
 ethical codes and laws, 41
 expedited research categories, 55–56
 human subjects research, 40–41
 protocol modifications, 50–51
 complaints, 51

noncompliance, 51
 unanticipated problems, 51
 review, categories of, 44–46
 exempt review, 44–46
 expedited review, 44, 46
 full board review, 44, 46
 overview of, 44
 role of, 41–47
 study participants
 confidentiality, 47–50
 incentives to encourage participation, 50
 informed consent, 48–49
 responsibility to, 46–47
 telephone screening script for recruitment, 49, 60
 submission, preparation for, 50
 training requirements, 42
 institution-specific costs, 161–162
 integer variables, 77
 internal consistency, 71
 internal validity, 32–35
 of quantitative research, 125
International Classification of Diseases (ICD), 65–66, 67, 161
 International Committee of Medical Journal Editors (ICMJE) criteria, 195–196
 international normalized ratios (INRs), 28, 104
 International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 164, 165
 interquartile range (IQR), 76, 79
 interrupted time series designs, 24, 29
 interval data, 77
 interval variables, 77
 interventional studies, 22, 23, 25, 27–28
 intervention group, 27
 interviewer bias, 34
 interview guide, creating, 119–121
 interviews
 asking questions, 118
 conducting, 116–117
 focus groups compared to, 110–111
 ground rules for, 111
 in-depth (IDIs), 106, 110, 113, 116
 individual *versus* focus groups, 110
 interview guide, creating, 119–121
 length of, 116
 location of, 116
 overview of, 113
 planning, 114–121
 probing during, 118–119
 recruitment of participants and sampling strategies, 114–115
 sample size in, 115–116
 types of, advantages and disadvantages of, 120–121
 introduction, in manuscript, 190, 203
An Introduction to Codes and Coding (Saldana), 122
 introductory statement
 for electronic/web-based survey, 137, 145
 for in-person survey, 137, 145
 investigator bias, 34
 investigator triangulation, 125
 iterative process, 115

J

jargon, 118, 136
 JMP Statistical Discovery, 86
 journal for submission, selecting, 188–189

K

key informant interviews (KII), 113
 keywords, in manuscript, 197, 203
 Kruskal–Wallis test, 85

L

leading questions, 118
 less structured interview, 120
 Likert scales, 135, 140
 line graphs, 180
 linking file, 48
 list-based sample frame, 133
 literature review, 8–10
 Excel spreadsheet with study description, 9
 purpose of, 8
 reference management resource, 9–10
 search results, 8–9
 search strategy, 8
 loaded question, 136
 logistic regression, 82, 83, 85
 low facilitator involvement, 117

M

mail-based surveys, 133–134
 Manitoba Centre for Health Policy, 71
 Mann–Whitney U test, 85
 manuscript, writing, 189–195
 abstract, 190, 202–203
 acknowledgments, 193, 204
 background information, 190
 conclusions, 193, 203
 conflicts of interest, 193, 204
 copyright permissions, 193
 cover letter, 188, 202
 discussion, 192–193, 203
 introduction, 190, 203
 keywords, 197, 203
 methods section, 190–191, 203
 outline, sample of, 202–204
 purpose, 190
 references, 194, 204
 reporting guidelines, 191
 results, 192, 203
 tables and figures, 194–195, 204
 title of, 190
 title page, 190, 202
 manuscript preparation and submission, 187–204
 co-authors, 195–197
 authorship criteria, 195–197
 feedback, 197
 journal for submission, selecting, 188–189
 keywords for manuscript, 197, 203
 peer review, 197–198
 reviewer comments, 198–199
 writing your manuscript, 189–195 (See *also* manuscript, writing)
 Markov model, 149, 153, 155
 matching, 30
 MATLAB, 163
 maturation bias, 29
 maximum variation case selection, 115

MAXQDA, 124
 McNemar's test, 82, 83
 mean, 78, 79, 83
 measures of association, 92–98
 absolute measures
 absolute risk reduction/increase, 93–94
 defined, 92
 number needed to harm (NNH), 95
 number needed to treat (NNT), 94
 contingency table, 92
 relative measures
 defined, 92
 hazard ratios (HRs), 97–98
 odds ratio (OR), 95–97
 relative risk (RR), 92–93
 measures of central tendency, 77, 78–79
 measures of data variability, 79–80
 measures of dispersion, 77
 median, 76, 78, 79
 MedWatch reports, 40
 member check, 126
 memoing, 107
 Mendeley, 10, 194
 Methods of Economic Evaluation of Health Care Programmes, 165
 methods section
 in abstract, 172
 in manuscript, 190–191, 203
 in study protocol, 19
 method triangulation, 125
 Microsoft Excel, 9, 63, 67, 68, 69, 71, 86, 163
 Microsoft Word, 63–64, 135
 Minitab, 86
 mirroring, 119
 misclassification bias, 34
 missing at random, 70
 missing completely at random, 70
 missing data, 70
 missing not at random, 70
 mixed methods research, 104
 mixed-mode surveys, 134
 mode, 78, 79
 mode effects, 134
 model cycle length, 156
 Monte Carlo simulations, 159
 multiple choice research questions, 135, 138
 multiple comparison procedures, 83
 multiple linear regression, 86
 multivariable procedures, 85–86
 multivariable regression analysis, 84, 85–86
 multivariate sensitivity analysis, 158

N

narrative research, 105, 106
 National Inpatient Sample (NIS), 161
 National Institute for Health and Care Excellence (NICE), 164
 National Institutes of Health, 42
 National Research Act, 41
 net monetary benefit (NMB), 149, 164, 169
 net present value, 156
 no comparator questions, 136
 nominal data, statistical tests for, 82–83
 nominal variables, 76, 77
 nondirectional hypothesis, 12–13

non-normal distribution of data, 78, 80–81
 nonparametric methods, 81
 nonresponse bias, 134, 140, 141
 nonresponse errors, 141
 nonverbal probe, 119
 normal distribution of data, 80–81
 normally distributed data, 78
 null hypothesis, 12–13, 81
 number needed to harm (NNH), 95
 number needed to treat (NNT), 94
 Nuremberg Code, 41
 NVivo, 124

O

objectives, writing, 11–12
 objectivity, of quantitative research, 125
 observational study designs, 24, 30–32
 case-control studies, 22, 24, 30–31
 cohort studies, 22, 24, 25, 31–32
 odds ratio (OR), 30, 95–97
 Office for Human Research Protections (OHRP), 42, 43, 50, 51
 one-way sensitivity analysis, 157–158
 open access journals, 188
 open-ended questions, 116, 117, 118, 135
 open source content, 188
 oral history, 106
 ORCID iD, 196
 ordering bias, 142
 ordinal data, statistical tests for, 84–85
 ordinal variables, 76, 77
 outcome frequency, measures of, 91–98
 measures of association, 92–98
 rate, 92
 risk, 91–92
 outcomes and quality-of-life data, 162–163
 outcome variable, 87
 outliers, 71, 78
 outpatient costs, 161
 oversampling, 133

P

paired *t*-test, 83
 Paperpile, 10
 paradigmatic case selection, 115
 parametric tests, 81
 participants. *See* study participants
 payer perspective, 155
 PDF files, 176
 peer review, 197–198
 process, 174
 of qualitative data, 125
 reviewer comments, 198–199
 peer-reviewed journal, 189
 percentiles/quartiles, 79–80
 performance improvement (PI), 43
 personally identifiable information (PII), 40
 perspective, 149, 155
 pharmacoeconomic analyses, 147–169. *See also*
 economic model
 considerations for, 165–166
 data
 cost, 161–162

- outcomes and quality-of-life data, 162–163
 - presentation of, 164–165, 169
- interpretation of, 163–164
- results, application of, 165
- software for running, 163
- types of, 149–152
 - budget impact analysis (BIA), 151–152
 - cost-benefit analysis (CBA), 150
 - cost-effectiveness analysis (CEA), 150–151
 - cost-minimization analysis (CMA), 150
 - cost-of-illness (COI) analysis, 149–150
- pharmacoeconomics
 - defined, 147
 - role of, 147–148
 - terminology in, 148–149
- phenomenology, 105, 106
- PICOTS criteria, 3–6
 - comparison group, 4, 5
 - intervention, 4, 5
 - outcomes, 4–5
 - population, 4, 5
 - setting, 5, 6
 - timeline, 5
- pie charts, 180
- piloting of questions, 138–139
- platform presentations, 177–181
 - components of, 177–181
 - acknowledgments, 179
 - background, 177–178
 - discussion, 179
 - methods, 178
 - results, 178–179
 - delivering, 181–182
 - slides for, developing and presenting, 177–181
 - text *versus* tables and figures, 180–181
- population. *See* study population
- poster presentations, 175–177
 - checklist for creating effective poster, 175
 - engaging your audience, 176–177
 - formatting, 175–176
 - key tips for, 176
- power, 87
- power calculations, 87
- pre-post study design, 23, 28–29
- pre-testing questions, 138–139
- prevalence, 26, 30
- primary data, 62
- primary objective, 12
- principal investigator (PI), 112
- probabilistic sensitivity analyses, 159
- probing, 118–119
- ProQuest RefWorks, 10
- prospective cohort studies, 25, 31
- protected health information (PHI), 40, 41, 48
- protocol modifications, in surveys, 138
- PubMed, 10
- purpose, of manuscript, 190
- purposive sampling, 114
- p* values, 98
 - coding frame/codebook, 122–123
 - emerging themes, 124
 - software packages for analysis, 124
 - transcription, 121–122
- reliability and validity of, 124–126
 - principles of, 125–126
 - validity strategies, 125–126
- trustworthiness of, 125–126
 - extensive quotes, 125
 - external audits, 125
 - member check, 126
 - peer review or debriefing, 125
 - thick, rich description, 125
 - triangulation, 125
- Qualitative Inquiry and Research Design* (Creswell), 106
- qualitative research, 103–129
 - approaches to, 105–108
 - case studies, 105, 107–108
 - ethnography, 105, 107
 - grounded theory, 105, 106–107
 - narrative research, 105, 106
 - overview of, 105–106
 - phenomenology, 105, 106
 - appropriate use of, 104–105
 - data collection methods, 108–121
 - focus groups
 - IRB considerations in, 111–113
 - overview of, 109
 - seven key steps, 108–111
 - defined, 104
 - IRB considerations in, 111–113
 - informed consent, 111
 - location of data collection, 112
 - number of participants, 111–112
 - recording data, 112
 - storing data, 112–113
 - use of incentives, 112
 - publishing, 126
 - quantitative research compared to, 104
 - strategies, 118, 135
 - validity and reliability terms in, 125
- quality-adjusted life year (QALY), 149, 150–151, 164, 165, 166
- quality assurance (QA), 43
- quality improvement (QI), 43
- quality-of-life (QOL), 150–151, 162–163
- Qualtrics, 134, 139, 142
- quantitative data, 75–90. *See also* biostatistics
- quantitative research, 3
 - primary data in, 62
 - qualitative research compared to, 104
 - sample size in, 115
 - strategies, 135
 - validity and reliability terms in, 125
- quasi-experimental designs, 22, 23, 28–29
- questionnaires, 135
- questions. *See* research questions
- QuickVoice Recorder, 112
- quota sampling, 114
- quotes, direct, 125

Q

- QR code, 176
- qualitative data
 - analyzing, 121–124
 - code data, 123–124

R

- R (software), 71, 86
- randomized controlled trial (RCT), 27–28

- randomized studies
 - experimental, 23, 25
 - interventional, 22, 23, 25, 27–28
- random sampling, 114, 133
- range, 79–80
- ranking, 136
- rate, 92
- rating scale, 135
- ratio variables, 77
- recall bias, 33, 142
- recording applications, 112
- recording data, 112
- REDCap, 71, 134, 139, 142
- redundant data, 115
- reference management resource, 9–10
- Reference Manager, 194
- references
 - in manuscript, 194, 204
 - in study protocol, 19
- reflecting, 119
- regression, 83–84
- regression to the mean, 29
- relational research questions, 3
- relative measures
 - defined, 92
 - hazard ratios (HRs), 97–98
 - odds ratio (OR), 95–96
 - relative risk (RR), 92–93
- relative risk (RR), 92–93
- relative risk reduction, 93
- reliability, of quantitative research, 125
- repeated-measures ANOVA, 83
- reporting bias, 33
- reporting guidelines, in manuscript, 191
- research
 - categories, expedited, 55–56
 - defined, 40
 - noncompliance, 51
 - secondary, 44, 46
- research findings
 - presenting (See abstract preparation)
 - publishing (See manuscript preparation and submission)
- research idea, 1–19
 - collaborating with research team, 13–14
 - items for discussion, 14
 - successful collaborations, 14
 - conceiving, 2–7
 - hypothesis, formulating, 12–13
 - literature review, 8–10
 - Excel spreadsheet with study description, 9
 - purpose of, 8
 - reference management resource, 9–10
 - search results, 8–9
 - search strategy, 8
 - objectives, writing, 11–12
 - research question, developing
 - FINER criteria for, 6–7
 - PICOTS criteria for, 3–6
 - study outcomes, specifying, 13
 - study protocol
 - background, writing, 11
 - methods, determining, 11
 - outline, 19
 - study timeline, 14–16
 - Gantt chart, 15–16
 - sample timeline, 15
 - in study protocol, 19
 - research-in-progress, 172
 - research note, 188
 - research questions
 - about IRB approval process, 42–43
 - causal, 3
 - descriptive, 3
 - developing
 - FINER criteria for, 6–7
 - PICOTS criteria for, 3–6
 - fixed-response, 135–136
 - interview, 118
 - multiple choice, 135
 - open-ended, 116, 117, 118, 135
 - piloting of, 138–139
 - poorly designed, 136
 - in presentation delivery, 182
 - pre-testing, 138–139
 - questionnaires, 135
 - relational, 3
 - types of, 135–136
 - yes/no, 135
 - respondents, 131. *See also* study participants
 - response bias, 141
 - response rates, 132–133
 - re-storying, 106
 - results
 - in abstract, 173
 - in manuscript, 192, 203
 - retrospective cohort studies, 25, 31, 32
 - Rev, 122
 - reviewer comments, 198–199
 - Revised Common Rule, 40, 41, 43, 44
 - risk, 91–92
 - R Studio, 163

S

- sample size
 - estimation of, 87–88
 - in focus groups, 115–116
 - identifying, 109
 - in interviews, 115–116
 - in survey planning, 132–133
- sampling
 - defined, 114
 - methods, 132–133, 139
 - strategies, 114–115
- sampling frame, 132–133
- SAS, 71
- saturation, 115
- scatter plot, 83–84, 159–160
- Scribble, 122
- seasonal variances, 29
- secondary data, 62–63
- secondary objectives, 12
- secondary research, 44, 46
- security, 124
- selection bias, 33
- sensitivity analysis, 149, 157–159
 - multivariate, 158
 - one-way, 157–158
 - probabilistic, 159
 - univariate, 157–158
- sharedness, 140
- simple linear regression, 83–84

- simple randomization, 27
- skewed data, statistical tests for, 84–85
- slides, for platform presentations, 177–181
- snowball sampling, 114, 115
- Social Cognitive Theory, 123
- social desirability bias, 141
- societal perspective, 155
- software
 - for analyzing qualitative data, 124
 - to assist with data analysis, 86
 - to assist with data collection, 69
 - reference management packages, 194
 - for running pharmacoeconomic analyses, 163
- SoundCloud, 112
- SoundNote, 112
- Spearman's Rho, 85
- spreadsheet tools, 9, 63, 67, 68, 69, 71, 86, 163
- standard deviation, 79–80
- Standards for Reporting Qualitative Research (SRQR), 126, 191
- Stata, 71, 86
- Statistical Analysis Software (SAS), 86
- statistical inference, 81. *See also* inferential statistics
- Statistical Package for the Social Sciences (SPSS), 86
- statistical packages, 86
- statistical tests, 82–85
 - for continuous data, 83–84
 - for nominal data, 82–83
 - for ordinal or skewed data, 84–85
- statistical *versus* clinical significance, 99
- stratified randomization, 28
- stratified sampling, 114
- Students *t*-test, 83
- study data, 61–73
 - data problems and limitations, 70–72
 - data quality, 71
 - duplicate data, 71
 - missing data, 70
 - outliers, 71
 - organization of, 63–70
 - data collection platforms, 68–70
 - data collection tool, 64–69
 - protocol changes, tracking, 63–70
 - sources, 61–63
 - primary data, 62
 - secondary data, 62–63
- study design, 21–38
 - ambispective studies, 25, 31, 35
 - analytic, 22, 24, 27–29
 - quasi-experimental designs, 22, 23, 28–29
 - randomized/interventional studies, 22, 23, 25, 27–28
 - data collection, considerations for, 35–36
 - inclusion and exclusion criteria, 36
 - study population, 36
 - timeframe, 35
 - descriptive, 22, 25–27 (*See also* qualitative research)
 - case report or case series, 22, 25–26
 - cross-sectional studies, 22, 23, 26–27
 - internal and external validity, 32–35
 - observational, 24, 30–32
 - case-control studies, 22, 24, 30–31
 - cohort studies, 22, 24, 25, 31–32
 - overview of, 22–25
 - randomized experimental studies, 23, 25
 - selection of, 22–25
- study findings, 91–101
 - confidence intervals, 98–99
 - outcome frequency, measures of, 91–98
 - measures of association, 92–98
 - rate, 92
 - risk, 91–92
 - p* values, 98
 - statistical *versus* clinical significance, 99
- study hypothesis, 12–13
- study objectives/hypothesis, in study protocol, 19
- study outcome, 13
- study participants
 - access to, 108–109
 - anonymity of, 112
 - confidentiality, 47–50
 - incentives to encourage participation, 50
 - informed consent, 48–49
 - creating, 48–49
 - elements of, 48
 - verbal, 49, 56
 - waiving requirement for, 48, 111
 - written, 57–59, 111
 - number of, 111–112
 - participant complaint, 51
 - in randomized controlled trial (RCT), 27–28
 - recruitment of, 114–115
 - responsibility to, 46–47
 - telephone screening script for recruitment, 49, 60
- study population, 36
 - of focus, 108
 - target, 113, 155
- study protocol
 - background, writing, 11
 - methods, determining, 11
 - outline, 19
 - sample of, 19
- study timeline, 14–16
 - Gantt chart, 15–16
 - sample timeline, 15
 - in study protocol, 19
- surveillance bias, 33
- survey
 - data analysis and validity, 139–141
 - objectives, 132
 - overview of, 131–132
 - survey delivery, mode of, 133–134
 - electronic/web-based surveys, 134
 - face-to-face methods, 113, 116, 133, 142
 - mail-based surveys, 133–134
 - mixed-mode surveys, 134
 - telephone-based surveys, 133
- survey design, 131–145
 - data storage and security, 139
 - dissemination and publication, 142
 - limitations and biases of survey research, 141–142
 - survey data analysis and validity, 139–141
 - survey planning, 132–138
 - tips, 136–137
- survey instruments, 134–138
 - preparation and construction of, 138
 - survey design tips, 136–137
 - survey questions, 135–136
 - fixed-response, 135–136
 - open-ended, 116, 117, 118, 135
 - pre-testing and piloting of, 138–139
- SurveyMonkey, 134, 139, 142
- survey planning, 132–138
 - IRB considerations for surveys, 137–138
 - anonymity and confidentiality, 137

survey planning (continued)
 incentives, 138
 informed consent, 137
 introductory statement, 137, 145
 protocol modifications, 138
 sample size and response rates, 132–133
 survey delivery, mode of, 133–134
 survey instruments, 134–138
 preparation and construction of, 138
 survey design tips, 136–137
 survey questions, 135–136
 survey objectives, 132
 survey research
 data storage and security, 139
 defined, 131
 dissemination and publication, 142
 limitations and biases of, 141–142
 pre-testing and piloting of questions, 138–139
 survey data analysis and validity, 139–141
 survey instruments, 134–138
 survey planning, 132–138
 systematic investigation, 40

T

tables and figures
 in manuscript, 194–195, 204
 text *versus*, 180–181
 table shells, 189
 telephone-based surveys, 133
 telephone screening script for recruitment, 49, 60
 telephonic survey administration, 138
 text *versus* tables and figures, 180–181
 themes, 124
 theoretical sampling, 107, 115
 theoretical saturation, 106
 Theory of Planned Behavior, 123
 theory triangulation, 125
 time horizon, 149, 155–156
 time series designs, 23, 29
 title
 of abstract, 172, 173
 of manuscript, 190
 title page
 in manuscript, 190, 202
 in study protocol, 19
 traditional journals, 188
 Transcribe (application), 122
 transcription, 121–122
 applications, 122
 errors, 71
 transferability, of qualitative research, 125
 Transtheoretical model, 123
 TreeAge, 163
 trends, 29
 triangulation, 125
 Trint, 122
 trustworthiness of qualitative data, 125–126
 extensive quotes, 125
 external audits, 125
 member check, 126
 peer review or debriefing, 125
 thick, rich description, 125
 triangulation, 125

t-test, 83, 84
 Tufts CEA Registry, 162
 2018 Requirements, 40
 two-sample t-test, 83
 two-way ANOVA, 83
 Type I error, 87
 Type II error, 87

U

uncertainty analysis, 157–160
 multivariate sensitivity analysis, 158
 one-way sensitivity analysis, 157–158
 probabilistic sensitivity analyses, 159
 undue influence, 50
 univariate sensitivity analysis, 157–158
 utility, 149, 150–151

V

validity
 bias in, 32–35
 defined, 32
 internal and external, 32–35
 survey data analysis and, 139–141
 value of a statistical life, 150
 variables, 76–77
 confounding, 32, 34
 continuous variables, 76–77
 dependent, 32, 34
 discrete, 76, 77
 list of, 64–65
 verbal consent script
 elements of, 49
 example of, 56
 verbal informed consent, 49, 56
 Veterans Affairs Federal Supply Schedule (VA FSS), 161
 visual analog scale, 135, 138
 Visual Basic, 163
 Voice Record Pro, 112

W

web-based surveys, 134
 wholesale acquisition cost (WAC), 161
 Wilcoxon Signed Rank test, 85
 willingness-to-pay (WTP), 149, 159, 164
 wish bias, 33
 within-case analysis, 108
 word processing program, 63–64
 written informed consent, 57–59, 111

X

zig-zag process, 107
 Zotero, 10

Y

yes/no research questions, 135, 138